Alessandro Riva, M.D.
Alessandro Riva, M.D., joined our Board of Directors in February 2022.
Dr. Riva is Chief Executive Officer of Intima Bioscience, a privately held clinical-stage gene and cell therapy company and serves on the Board of Directors of Century Therapeutics, a NASDAQ-listed biotechnology company developing innovative iPSC-derived NK and T cell therapies. Prior to joining Intima, he served as Chief Executive Officer at privately held Ichnos Sciences, where he built a biotechnology company focused on bi- and tri-specific antibodies in oncology and biologics in autoimmune diseases.
Before Ichnos, he was Executive Vice President and Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma. Prior to Gilead, Dr. Riva was Executive Vice President and Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals, where he contributed significantly to the Oncology Business Unit and the Cell and Gene Therapy Unit. He was also interim President of Novartis Oncology during the acquisition of GSK Oncology. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer and Aventis, and co-founded the Breast Cancer International Research Group (BCIRG) and the Cancer International Research Group (CIRG), where he served as CEO.
He received his M.D. in medicine and surgery from the University of Milan and a board certification in oncology and hematology from the same institution.